All In Biotech

Drug Trial Radar · NCT02516241

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,126 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,126

Actual

Start

Nov 2, 2015

Primary completion

Jan 27, 2020

Study completion Dec 31, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 5, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer

Conditions

  • Urothelial Cancer

Interventions

  • MEDI4736 (Durvalumab)Drug

    IV infusion

  • TremelimumabDrug

    IV infusion

  • CisplatinDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • GemcitabineDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis SetTime frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
  2. To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis SetTime frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

Locations

222 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Stanford, California

  • Research Site

    Aurora, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Louisville, Kentucky

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Detroit, Michigan

  • Research Site

    Omaha, Nebraska

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Memphis, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Seattle, Washington

  • Research Site

    Box Hill, Australia

  • Research Site

    Elizabeth Vale, Australia

  • Research Site

    Macquarie University, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Waratah, Australia

  • Research Site

    Linz, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Brussels, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Barretos, Brazil

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Ijuí, Brazil

  • Research Site

    Itajaí, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

Showing 40 of 222 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.